Publicacións en colaboración con investigadores/as de Dana–Farber Cancer Institute (6)

2023

  1. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

    Blood Advances

2012

  1. Phase i studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

    Investigational New Drugs, Vol. 30, Núm. 3, pp. 1121-1131

2010

  1. International network of cancer genome projects

    Nature, Vol. 464, Núm. 7291, pp. 993-998

1996

  1. Adhesion of multiple myeloma cells to the bone marrow microenvironment: Implications for future therapeutic strategies

    Molecular Medicine Today, Vol. 2, Núm. 10, pp. 425-431

  2. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein

    Blood, Vol. 88, Núm. 6, pp. 2219-2227

  3. Transforming growth factor-β1: Differential effects on multiple myeloma versus normal B cells

    Blood, Vol. 87, Núm. 5, pp. 1928-1938